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Abstract Respiratory syncytial virus (RSV) is a highly contagious virus, and is themajor
cause of lower respiratory tract infections in infants and toddlers worldwide. RSV
infection poses serious health risks to young children during the first 2 years of
life. Several infant populations have been classified as high risk, and additional
risk factors are known to increase the likelihood of severe RSV infection. Treat-
ment for active RSV infection is limited to the symptoms of infection rather than
the underlying cause; therefore, it is critical to reduce the transmission of RSV.As
nurses, we highlight the importance of educating healthcare professionals, both in
the hospital and community settings, aswell as parents and other caregivers about
the risks and outcomes associated with RSV infection, and necessary measures to
decrease the risk of infection. We also highlight the importance of the successful
identification of those children who are at high risk of RSV infection. RSV pro-
phylaxis (RSVP) with palivizumab has been shown to improve clinical outcome
in infants who are considered high risk compared with those who have not re-
ceived RSVP. The failure of healthcare staff and primary caregivers to protect
children against an RSV infection can have lasting detrimental effects on the
health and lives of affected children and their families.
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1. What is Respiratory Syncytial Virus
(RSV)?
First identified as a human pathogen in 1956,[1]
respiratory syncytial virus (RSV) is a single-
stranded, enveloped, RNA pneumovirus that in-
fects respiratory epithelial cells in susceptible
infants. The F glycoprotein on the surface of the
virus participates in viral attachment and medi-
ates the process of fusion between the virus and
cell membranes, as well as between infected cell
membranes, resulting in ‘syncytia’ formation.
There are two subtypes of RSV, type A and type
B, which differ in the envelope proteins on the
viral shell. Both subtypes circulate annually, and
both are infectious; however, there is some evi-
dence that type A is the more common cause of
RSV infections[2,3] and may lead to more severe
disease.[4] The virus is highly contagious and is
the major cause of lower respiratory tract in-
fections in infants worldwide. Nearly all children
have been infected by RSV by 2 years of age.[5,6]
Autoimmunity to infection in infants is often in-
complete and, therefore, reinfection by RSV is
common;[7] however, symptoms from subsequent
infections are typically less severe.[8] The virus is
primarily spread through large particle aerosols
(due to coughing or sneezing) or by fomites fol-
lowed by self-inoculation. RSV can survive on
non-porous surfaces for 6–7 hours, porous sur-
faces such as hospital gowns for 2 hours, and the
skin for 20–30 minutes.[9-11] These characteristics
make transmission quite likely among children
and infants in close contact with each other or
with infected caregivers if preventive measures
are not strictly followed.
2. Burden of RSV Disease
Although RSV infection often manifests as a
mild cold in otherwise healthy adults and can be
dismissed as an insignificant nuisance, it can se-
riously affect many children. It is the leading viral
cause of infant mortality, and may cause 7- to
9-fold more deaths than influenza.[12] A recent
study by Sampalis[13] demonstrated that hospi-
talization due to RSV infection leads to increased
risk of morbidity and mortality, and increased
healthcare resource utilization. The rate of res-
piratory admissions due to RSV for infants aged
<6 months is substantially higher than for any
other viral cause, including influenza.[14] Hospi-
talization for bronchiolitis or pneumonia due to
RSV infection can result in additional burdens,
such as admission to the pediatric intensive care
unit, oxygen supplementation, and mechanical
ventilation. Apnea, which may be one of the first
signs of RSV disease,[15] is present in 16–20% of
young infants. Kneyber et al.[16] also demonstrated
that the presence of apnea at hospital admission
was related to expression of recurrent apnea and
subsequent increased likelihood of mechanical
ventilation. In addition, infants or children with
active RSV infections may require the cancella-
tion of necessary surgical procedures for under-
lying medical conditions, specifically those with
cardiac anomalies requiring urgent surgery, add-
ing to the risk of additional medical complica-
tions. Hospitalization can cause significant dis-
ruption of the lives of the families of affected
infants, and can lead to increased emotional and
financial burdens. The financial burden is not
limited to the direct hospital costs for in-patient
care and cancellation of scheduled procedures,
but also reflects indirect costs such as trans-
portation (which can be substantial for isolated
groups), lost wages, food, and daycare for other
children in the family.
Adding to the potential cost of infection by
RSV is that children with severe RSV infections
are more likely to develop ongoing medical prob-
lems. Infants hospitalized with RSV infection
often have difficulties with feeding, which can
persist after recovery from the acute infection.[13]
Additionally, Stein et al.[17] demonstrated that
hospitalized infants diagnosed with RSV-associated
lower respiratory tract infections were 3.2- and
4.3-fold more likely to develop infrequent and
frequent wheezing, respectively, by 6 years of age.[17]
Sigurs et al.[18] also reported that RSV-associated
bronchiolitis in childhood (severe enough to cause
hospitalization) was a risk factor for the develop-
ment of asthma or recurrent wheezing at 13 years
of age.[18] Infants with RSV infection are also more
likely to need re-hospitalization for respiratory
conditions (such as bronchiolitis or pneumonia)
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and other conditions (such as anemia or anorex-
ia) after recovery from their initial RSV dis-
ease.[13] Older children who had been hospitalized
with severe RSV infection as infants are often
required to make repeat visits to clinics to address
the long-term complications (such as recurrent
wheezing and asthma) that occur as a consequence
of their earlier RSV infection. These potential
additional healthcare and emotional costs add to
the overall burden of RSV infection.
3. Risk Factors for Severe RSV Infection
All infants are at risk of RSV disease resulting
from infection by the virus; however, certain
populations of neonates, medically fragile infants
and young children are at higher risk of acquiring
severe RSV infection. Premature infants, partic-
ularly those of less than 34 weeks’ gestation, are
at especially high risk, owing to their reduced
immune system function and underdeveloped
respiratory system.[19,20] There is also evidence
that late-preterm (near-term) infants (born between
34 weeks’ and 36 weeks and 6 days’ gestation)
are at increased risk.[21-23] This may partially be
due to the fact that while pulmonary function is
physiologically premature (inadequate surfac-
tant, incomplete alveolar development, impaired
gas exchange),[22] outward physical character-
istics (e.g. bodyweight) make these infants appear
more like full-term infants. Hence, they may be
treated more like full-term infants, rather than
being treated with some of the necessary precau-
tionary measures given to other premature in-
fants.[22] While severe RSV infection has most often
been associated with younger age (<6 months),
there is emerging evidence that the prevalence of
acute lower respiratory infection caused by RSV
is increasing in relatively older, more mature in-
fants (aged 6–11 months).[24]
Infants and toddlers suffering from chronic
lung disease and congenital heart disease (CHD)
have a higher risk of hospitalization and fatality
resulting from RSV infections,[25] as do children
with cystic fibrosis and pulmonary hypoplasia,[26,27]
Down syndrome,[28] neuromuscular disease, and
severe immune system compromise.[29] The pres-
ence of these severe underlying co-morbid con-
ditions, including malignancies, is associated with
mortality among term and older children with
RSV infection.[25] It also appears that boys have a
higher risk of having complications associated
with RSV infection than girls. This may be due to
the narrower and shorter airways relative to lung
size in boys, resulting in lower levels of airway
conductance, which in turn makes airway obstruc-
tion from respiratory tract infection more com-
mon.[30] Generally, birthweight contributes to
risk, as infants with low birthweight for their
gestational age are more likely to have compli-
cations associated with RSV infection.[23] While a
high percentage of these ‘high-risk’ children are
hospitalized due to complications from severe RSV
infection, a higher overall percentage of hospitalized
children derive from non-high-risk groups.[31] This
highlights the importance of educating all parents
and healthcare staff about the transmission of RSV,
since it applies to all infants and children, not just to
those considered ‘high risk.’
There are additional risk factors that increase
the susceptibility of newborns to RSV infection
(see table I). In northern latitudes, the ‘RSV season’
Table I. Factors that contribute to increased risk of severe respira-




hemodynamically significant congenital heart disease[25,32]





Low birthweight for gestational age[23,33]
Young chronologic age (£12 weeks at start of RSV season)[34-36]
Attendance in daycare centers[36-38]
Presence of pre-school or school-aged sibling(s)[35-37,39]
High number of people in home or multiple people sharing a
bedroom[38,40]
Not breastfeeding[37]
Exposure to tobacco smoke[41,42]
Family history without eczema[43,44]
a Specific risk factors may vary in impact depending on geographic
region and ethnic population.
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typically runs from early winter (November/
December) through late spring (April/May). It is
during this time that the rate of hospitalization
due to RSV infection is highest,[14] making this a
particularly important time for caregiver vigilance
and appropriate prevention measures. However,
it has been demonstrated that RSV infections can
occur at any time of year,[21,45] highlighting the
importance of year-round education and infec-
tion reduction measures. Other risk factors that
may increase an infant’s susceptibility to RSV
were reviewed by Simoes,[37] and include attend-
ance in daycare and having pre-school or school-
aged sibling(s). Also, higher numbers of people
sleeping in the same room has been shown to in-
crease the risk of hospitalization due to respira-
tory tract infection.[38,40] It is generally thought
that breastfeeding confers some protection against
RSV-associated lower respiratory tract infec-
tion,[37] such that children who are not breastfed
are at increased risk. The air quality within the
home is of importance as well; exposure to to-
bacco smoke may cause increased respiratory
tract reactivity in susceptible infants, leading to
exacerbation of respiratory disease.[41,42]
4. Strategies for Reducing the Risk of RSV
Infection
4.1 Education
Due to the severity of RSV disease, and the
ease with which the virus is transmitted, an edu-
cation program for all healthcare providers, in-
cluding parents and other caregivers, should be a
priority (see table II). For primary caregivers, the
focus needs to include the identification of those
children at risk of severe RSV disease, the char-
acteristics of the virus itself, the mode of virus
transmission, and the symptoms of infection, re-
gardless of the risk status of children. Education
sessions should also include demonstrations of
diligent hand washing, as hand hygiene is a cru-
cial element in infection control. Traditionally,
hand washing has been performed with soap and
water; however, alcohol-based hand rinses and
gels have been shown to be effective in removing
microorganisms from hands (reviewed by Boyce
and Pittet[46]). Additionally, information should
be provided on proper disinfecting of susceptible
surfaces and other areas where RSV can be
found. Because of its potential to reduce the risk
of RSV susceptibility (and provide other health
benefits), breastfeeding should be encouraged.
Education about the potential consequences of
severe RSV disease, including its contribution to
persisting health problems, is highly important.
Education points for reducing the risk of RSV
transmission are outlined in table II and specifi-
cally addressed in sections 4.2 and 4.3.
4.2 Reducing Community-Acquired Infection
In the community setting, children at risk of
RSV infection are typically healthier (not re-
quiring hospitalization), but are being cared for
in clinics and doctors’ offices where prevention
guidelines and practices may be less rigorous or
non-existent (such as in waiting rooms). In an
outpatient clinic or doctor’s office, minor cold
symptoms may often be ignored, as RSVmay not
be as prominent in the minds of those who are
tending to children, specifically those children
Table II. Measures to reduce respiratory syncytial virus (RSV)
transmission
In the hospital/clinic
Hand hygiene: wash hands thoroughly with soap and warm water
before and after touching children. Hand sanitizer can be used if
hands are not soiled
Wear gloves, gowns, masks
Promptly identify all persons (patients, parents, and others) with
febrile respiratory illness in outpatient areas
Effectively isolate or cohort any infant(s) or child(ren) with cold
symptoms (cough, runny nose) even if not yet diagnosed with RSV
Promptly screen/test for RSV
Routinely disinfect susceptible surfaces, including toys and books,
in waiting rooms of offices and clinics
In the home
Hand hygiene: wash hands thoroughly with soap and warm water
before and after touching children. Hand sanitizer can be used if
hands are not soiled
Frequently wash children’s clothes, bedding and toys
Keep children away from crowded areas and from those who are sick
If parents are sick, minimize close contact with children
(avoid kissing)
Encourage and support breastfeeding
218 Bracht et al.
ª 2011 Bracht et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (3)
who do not have the significant risk factors listed
above. Additionally, it has been demonstrated
that during RSV outbreaks, infection of medical
staff is common, and the symptoms of such in-
fections can be dismissed as being caused by mild
colds or flu-like illnesses.[47] Indeed, caregivers
who have active RSV infections may even be
asymptomatic.[47]
The attention to diligent hand washing before
and after contact with patients cannot be over-
stated for reducing the risk of community-
acquired RSV infection. In outpatient clinics and
doctors’ offices, it is important for staff to wear
gloves, gowns, and masks, and to make every ef-
fort to immediately isolate any patient with cold
symptoms in an assessment room. It is also re-
commended to routinely disinfect susceptible
surfaces (including toys and books) in waiting
rooms. It may be best to remove toys and books
from waiting rooms altogether and encourage
families to bring their own toys, if needed. In the
home, primary caregivers should be instructed to
keep their children away from large crowds, areas
where people are sick, and areas where the chil-
dren may be exposed to tobacco smoke. When
parents are sick, they should make every attempt
to minimize close contact with the children and
avoid kissing.
4.3 Reducing Nosocomial Infection
Another important consideration regarding
the risk of infection by RSV is the potential for
nosocomial transmission. Welliver et al.[25] re-
cently reviewed the impact of nosocomial in-
fection, noting a study by Langley et al.[48] in
which a 10-fold higher mortality rate was found
in children with nosocomial infection compared
with those with community-acquired infection.
The risk of nosocomial transmission may be
higher in children who are being cared for in a
hospital’s neonatal unit or pediatric ward due to
the already compromised health of the child (ne-
cessitating hospitalization), and the high density
of patients and number of staff. RSV transmis-
sion may occur even though there may be
standard prevention guidelines in place in such
settings.[47] This risk may be increased due to a
delay in detecting and diagnosing RSV infection
in infants. Symptoms of RSV infection, such as
apnea, bradycardia, and changes in ventilation,
can often be attributed to causes other than
RSV.[49] The ability to quickly identify those in-
fants who may have an RSV infection can de-
crease the risk of nosocomial transmission. In
addition to the increased mortality risk, RSV in-
fection in hospitalized children can severely im-
pact their health status, and subsequently prolong
hospital stays.[47]
To reduce the likelihood of nosocomial trans-
mission, it is recommended to have an annually
updated, readily available, written policy for
hospital and clinic employees to follow, outlining
the important preventive steps. Hospital staff
should be educated about how to avoid RSV ex-
posure (by wearing gloves, gowns, masks, and,
where necessary, protective eyewear), and on the
importance of maintenance of hand hygiene by
thorough washing immediately before and after
contact with all children. It is a good idea to
conduct these training sessions just prior to the
start of the annual RSV season. Screening pro-
tocols for early RSV identification should be in
practice in neonatal and pediatric care facilities.
Hospitals should have a policy of immediately
isolating or cohorting infants who display cold
symptoms. In the ideal situation, infants should
be isolated and tested for the pathogen causing
the cold symptoms. Children should then be
grouped by underlying pathogen once it has been
identified (to reduce the likelihood of coinfection).
However, not all hospital facilities are equipped
to quickly diagnose the underlying cause of symp-
toms, or have the space to isolate each individual
child. In these cases, it is best to immediately cohort
children based on symptoms. A demonstration of
the effectiveness of these measures to control the
spread of RSV among hospitalized infants was re-
ported by Isaacs et al.[50] These authors showed that
when the prevention protocol was rigorously fol-
lowed, RSV infection contracted while in the hos-
pital decreased from 4.2% to 1.1% in non-CHD
infants, and from 34.8% to 3.3% in infants with
CHD. An added benefit of the implementation of
these measures is the potential to decrease the
transmission of other infective agents. Attention to
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these steps can help reduce the number of children
who develop severe RSV disease.
5. Outpatient Care for RSV Infection
The responsibility for outpatient care of pa-
tients with RSV infection rests with the primary
caregivers as well as physicians and nurses in of-
fices and clinics. Therefore, one of the key prior-
ities for outpatient care, in order to minimize the
likelihood of RSV infection, is the education of
the primary caregiver. This teaching should
include information on factors that contribute
to increased risk (table I). Additionally, there
should be a focus on the steps that can be taken to
minimize the risk of RSV transmission (high-
lighted in sections 4.2 and 4.3, and in table II).
The next step in outpatient care is the education
of the primary caregivers about the signs and
symptoms of RSV infection. Infection will typi-
cally present as a mild upper respiratory tract
illness with symptoms such as low grade fever,
cough, nasal congestion, vomiting, diarrhea, and
decreased food intake. Moderate symptoms in-
clude apnea (which may be the first symptom in
premature and/or very young infants[15]), irrita-
bility, tachypnea, increased coughing and wheez-
ing, diaphoresis, and dehydration. The disease
can progress to a lower respiratory tract infection
with severe symptoms of respiratory distress, in-
cluding lethargy, apnea, tachypnea, wheezing,
nasal flaring, grunting, retractions, and cyanosis.
Importantly, not all infected children will neces-
sarily demonstrate the same symptoms, which
can make diagnosis difficult. For example, apnea
is more common in preterm, younger infants with-
out fever.[51] It is important to educate caregivers
about these common symptoms so that they can
alert the child’s physician promptly upon their
appearance. If symptoms are sufficiently severe,
or if there are signs of worsening symptoms, the
physician may recommend admission to an in-
patient facility.
6. Inpatient Care for RSV Infection
Many treatment approaches, as recently suc-
cinctly reviewed by Paes et al.,[52] have been utilized
in patients with active RSV bronchiolitis. Treat-
ment with corticosteroids, including dexametha-
sone, prednisone, and inhaled corticosteroids,
has not resulted in clear improvements (reviewed
by Mitchell[53]) and is therefore not recommen-
ded. Additional approaches have included the use
of leukotrienes and ribavirin; however, they are
also not recommended due to a lack of evidence
for improving clinical outcomes.[53,54] Ribavirin,
an agent with broad-spectrum antiviral activity,
had previously been used to treat active infection,
but limited clinical effectiveness and potential
risks to patients and staff have led to decreased
use.[55] Bronchodilators can be used on an in-
dividual basis; however, their use should be con-
tinued only if there is evidence for therapeutic
benefit.[53] Antibiotics should be used only when
there is a strong suspicion of bacterial infection,
and should be stopped when cultures are shown
to be negative.[53] There is no evidence of posi-
tive therapeutic benefit of antibacterial treatment
for bronchiolitis. As a result, treatment of RSV
bronchiolitis currently focuses on supportive care,
including the administration of supplemental
oxygen when oxygen saturation is below 90%,
maintenance of fluid balance, and nutrition. When
necessary, mechanical ventilation with or without
extracorporeal membrane oxygenation is used to
maintain adequate oxygenation.
7. Immunoprophylaxis
The only currently available pharmacologic
prophylactic to decrease the risk of RSV infection
is palivizumab, a passively used monoclonal an-
tibody utilizing a humanized monoclonal anti-
body specific for the F protein of both subtypes
of RSV.[56,57] A pivotal clinical trial conducted in
children at high risk of RSV infection demon-
strated a significant reduction in RSV-related
hospitalization rate in those who received RSV
prophylaxis (RSVP) with palivizumab, in addi-
tion to a decreased length of stay in the hospital,
lower incidence of admission to the intensive care
unit, fewer days with increased supplemental
oxygen, and fewer days with moderate or severe
lower respiratory tract illness compared with
those who received placebo.[58] Results support-
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ing this initial trial have been obtained by other
researchers.[59,60] Feltes et al.[61] also demonstra-
ted the ability of RSVP to reduce hospitalization
rates in children aged £24 months with hemody-
namically significant CHD. Primary adverse ef-
fects associated with palivizumab therapy are
local erythema, pain at the injection site, upper
respiratory infection, fever, and rash, with very
rare cases of anaphylaxis reported.[56,57] Because
of its positive benefit and adverse-effect profile,
palivizumab has been approved for the pre-
vention of serious lower respiratory tract disease
caused by RSV in pediatric patients at high risk
of RSV disease.[32] While it has been shown to be
effective as a prophylactic measure, palivizumab
does not appear effective in reducing the severity
of active RSV infections.[62] However, if infants
contract RSV while receiving palivizumab in-
jections, RSVP should continue for the remainder
of the RSV season, as RSV infection does not
confer complete immunity; thus, continuation of
RSVPmay help to prevent reinfection in the same
year.[43]
One of the difficulties in the use of RSVP to
decrease RSV infection is the determination of
‘high-risk’ infants. Using the risk factors outlined
in table I, guidelines have been developed to de-
termine which children qualify for RSVP. These
guidelines may vary depending on the specific
country and region, and healthcare staff should
contact a regional health authority to determine
the approved qualifications for RSVP. There
may be certain populations who are at particular
risk for RSV disease due to their geographic iso-
lation or ethnic susceptibility. For example, in
Canada, Inuit populations are highly susceptible
to severe RSV infection, and infections are com-
mon throughout the year;[63] therefore, each prov-
ince in Canada has slightly different guidelines for
those children who qualify for RSVP.
The approved administration schedule for
RSVP is based on the clinically validated regimen
reported by the IMpact-RSV Study Group[58] and
includes monthly intramuscular injections through-
out the RSV season. In many cases, the first in-
jection (and sometimes subsequent injection) is
given in the hospital setting, with the completion
of the RSVP regimen occurring in outpatient
doctors’ offices or specialized RSV clinics. Im-
portantly, to date, it appears that palivizumab
can be administered along with other scheduled
vaccines without affecting their immunogeni-
city.[64] However, if a reaction were to occur with
coadministration, it would be difficult to deter-
mine the cause.
When given monthly as recommended, blood
concentrations of palivizumab are sufficient to
help improve clinical outcome measures in high-
risk infants.[58] However, just prior to the second
administration, trough serum antibody levels are
the lowest that they will be over the course of
RSVP.[65]Missing or delaying a dose of palivizumab
will cause the antibody level to drop further and
potentially increase susceptibility to RSV in-
fection. Therefore, it is essential that subsequent
doses of palivizumab be administered at the
scheduled time to ensure that antibody titers are
maintained at an effective level. Additionally, it
has been shown that children requiring cardio-
pulmonary bypass for cardiac surgery show sig-
nificant decreases in serum palivizumab concen-
trations after surgery.[57] It is recommended that
these children receive a dose of palivizumab as
soon as possible after surgery to promote effec-
tive prophylaxis.[43] Achieving and maintaining
target serum palivizumab concentrations may
not confer protection for all infants; furthermore,
it is possible that the diminished trough serum
concentration of palivizumab prior to its second
administration may increase the susceptibility of
infants to RSV infection. Therefore, increased
vigilance and adherence to the approved timeline
for RSVP and to other prevention measures may
improve the clinical outcome of high-risk infants.
In addition to the effectiveness of palivizumab
as a means of reducing the occurrence and se-
verity of RSV infection in high-risk infants,
RSVP has also been associated with lower rates
of recurrent wheezing by the time children have
reached 2–5 years of age.[66] In addition to this
important effect on the well-being of the infected
infants, successful RSVP may also provide bene-
fits for the infants’ primary caregivers. The re-
duction in duration of moderate or severe lower
respiratory tract illness and potential hospitaliza-
tion results in less time off work (and associated
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decrease in income), may help reduce trans-
portation and food costs associated with hospital
visits, and may also help reduce the need for al-
ternate care for siblings of the affected infant.
However, these potential benefits need to be
weighed against the costs associated with RSVP.
One recent report has shown that the hospital-
ization rate due to RSV infection for high-risk
infants (aged 0–6 months) ranges between 8%
and 56%, compared with 4.4% of infants who are
considered low risk.[67] Even with this relatively
high rate of hospitalization due to RSV infection,
economic cost-benefit analyses have yielded
conflicting results.[68-70] Recent Canadian studies
have reported that the cost effectiveness of RSVP
for infants of 33 to <36 weeks’ gestation was best
achieved when the Canadian risk-scoring tool
was used. The risk assessment tool provides the
nurse or doctor with a practical and efficient way
of identifying infants who are at low risk of ac-
quiring RSV, therefore excluding them from
RSVP - a subsequent cost saving.[71,72]
This highlights the need for appropriate deter-
mination of true high-risk infants to implement
the most cost-effective strategy for passive im-
munization while maintaining the highest possible
rates of effective RSV disease prevention. How-
ever, since children who score low on risk-
assessment measures may go on to develop severe
RSV disease, attention to risk-reduction tech-
niques is also of critical importance.
8. Strategies for Improving Adherence to
Immunoprophylaxis and Preventive
Measures
We feel that the best way to improve adher-
ence to preventive measures is to educate all those
who are in direct contact with susceptible chil-
dren about the basic characteristics and common
modes of RSV transmission and prevention. This
education can take the form of in-service educa-
tion, ‘lunch-and-learn’ sessions, and/or seminars
for doctors and nurses. Posters that demonstrate
ways to decrease the risk of infection can be dis-
tributed throughout healthcare facilities and doc-
tors’ offices. Parents and other caregivers may
need individual education and counseling as well
as information pamphlets that reinforce the
necessary risk-reduction information. Essential
topics for education are the specific ways to de-
crease risk of transmitting RSV (see table II), and
the necessity of adhering to the timelines for
RSVP in children who qualify for immuno-
prophylaxis. An important step is the successful
education about the long-term consequences that
can arise from the failure to adequately protect
children from severe RSV infection. We propose
that these education sessions occur just prior to
the start of each annual RSV season, reinforcing
the benefits of adhering to prevention protocols,
in order to maximize adherence throughout the
RSV season.
One additional way to improve the adherence
of parents and caregivers when the infants leave
the hospital is to ensure that there is effective
communication of medical and any other pertinent
information between the parents and healthcare
provider regarding scheduled immunoprophylaxis
requirements. Obtaining sufficient and accurate
contact information for the parents of discharged
infants allows clinic nurses and doctors’ offices
to initiate calls to remind families of upcoming
appointments for subsequent administrations of
RSVP. Also, providing families with an appoint-
ment card for the next appointment including
date, time, and office phone number, as well as
encouraging families to call should they have any
questions or concerns, improves the likelihood of
successful adherence. It is critically important that
families understand the impact of RSV disease so
that they can better advocate and follow through
with the necessary risk-reduction measures.
9. Potential Treatment Options for RSV
Infection in the Future
There are currently several treatment approaches
being investigated for RSV infection, as recently
reviewed by Empey et al.[62] These treatments
target different proteins associated with the rep-
lication and/or infection processes of the virus.
While these novel treatments are promising, they
are either in preclinical development or early
clinical trials, suggesting that, even if successful,
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they will not be clinically available for years to
come.
The promise of a vaccine for RSV has been a
discussion point for primary care providers for
some time. Unfortunately, due to several factors,
a safe and effective RSV vaccine has yet to be
developed. One primary factor contributing to
the unsuccessful development of a vaccine to
date is that the targeted population for the RSV
vaccine consists of young infants from birth to
6 months of age. These infants may have an in-
adequate response to vaccination due to their
underdeveloped and under-responsive immune
systems, and because of the potential for sup-
pression by maternally transmitted antibodies.[73]
A vaccination attempt in the 1960s using in-
activated RSV resulted in an exaggerated res-
ponse to the virus, followed by the hospital-
ization of 80% of the vaccinated infants and two
deaths.[74] This result has hampered the develop-
ment and testing of novel vaccine approaches.
New approaches to vaccine development are
exploring the use of live, attenuated viruses, ad-
ministered to infants intranasally.[75] Adminis-
tration directly to the nasal mucosa induces local
and systemic immunity, and also minimizes sup-
pression by maternally transmitted antibodies.
Intranasal administration may also confer greater
protection and higher immunogenicity. Ensuring
a balance between immunogenicity and successful
attenuation of live virus is of critical importance
to the successful development of an RSV vaccine.
There are currently several early clinical trials
that are aimed at examining the safety and
immunogenicity of novel vaccines.
10. Conclusions
RSV infection poses a serious health risk to
young infants and children, particularly during
the first 2 years of life. There are several catego-
ries of patients who are considered to be at high
risk of developing severe RSV infection, and ad-
ditional environmental factors may also contrib-
ute to the risk of developing severe RSV disease.
Severe RSV infection may be associated with
persistent and recurring health problems for
children, highlighting the need to reduce the rate
and severity of infection. Education of parents,
hospital staff, and nurses who are responsible for
the direct care of susceptible children is of critical
importance to reduce the transmission of RSV.
Education should focus on the characteristics of
RSV, routes of transmission, and proper tech-
niques for reducing the risk of transmission.
While treatment of active RSV infection is limited
and restricted to the symptoms of infection, high-
risk infants given palivizumab immunoprophylaxis
have a decreased rate of hospitalization and fewer
days with moderate or severe lower respiratory
tract illness compared with those who do not re-
ceive therapy. Identification of eligible infants is
critical to the successful implementation of im-
munoprophylaxis. Effective education and risk-
reduction techniques are crucial to minimize
infection of young children by RSV and to help to
reduce the burden of the disease.
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